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CD4CD25Foxp3 regulatory T cells
(Treg) play an important role in the
induction and maintenance of immune
tolerance. Although adoptive transfer of
bulk populations of Treg can prevent or
treat T cell–mediated inflammatory dis-
eases and transplant allograft rejection
in animal models, optimal Treg immuno-
therapy in humans would ideally use
antigen-specific rather than polyclonal
Treg for greater specificity of regulation
and avoidance of general suppression.
However, no robust approaches have
been reported for the generation of hu-
man antigen-specific Treg at a practical
scale for clinical use. Here, we report a
simple and cost-effective novel method
to rapidly induce and expand large num-
bers of functional human alloantigen-
specific Treg from antigenically naive
precursors in vitro using allogeneic non-
transformed B cells as stimulators. By
this approach naive CD4CD25 T cells
could be expanded 8-fold into alloantigen-
specific Treg after 3 weeks of culture
without any exogenous cytokines. The
induced alloantigen-specific Treg were
CD45ROCCR7 memory cells, and had
a CD4high, CD25, Foxp3, and CD62L
(L-selectin) phenotype. Although these
CD4highCD25Foxp3 alloantigen-specific
Treg had no cytotoxic capacity, their sup-
pressive function was cell-cell contact
dependent and partially relied on cyto-
toxic T lymphocyte antigen-4 expression.
This approach may accelerate the clinical
application of Treg-based immunotherapy
in transplantation and autoimmune dis-
eases. (Blood. 2008;112:2554-2562)
Introduction
CD4CD25Foxp3 regulatory T cells (Treg) are negative
regulators of immune responses to self- and foreign antigens and
play a critical role in maintaining immune tolerance by suppress-
ing pathologic immune responses in autoimmune diseases,
transplant allograft rejection, and graft-versus-host disease
(GVHD).1-3 On adoptive transfer in rodents, Treg were found to
control experimental autoimmune diseases,4 inhibit GVHD,5,6
and prevent transplant allograft rejection,7,8 indicating that
Treg-based therapy has a great therapeutic potential for these
diseases in humans.
An important obstacle to Treg-based therapy has been the
limited numbers of these cells that are available, as only
approximately 1% to 2% of circulating human CD4 T cells are
Treg. Several groups have developed protocols to expand a large
number of polyclonal CD4CD25 Treg in vitro with repeated
stimulation by either CD3 and CD28 mAbs or artificial antigen-
presenting cells (APCs) for activation through CD3 and CD28,
together with exogenous high-dose interleukin-2 (IL-2).9-11
However, polyclonal Treg may cause global immune suppres-
sion.4,7 In addition, because there are only few antigen-specific
Treg in the population of the polyclonal Treg, very large
numbers of nonspecifically expanded Treg are required to
inhibit bone-marrow allograft rejection in animal models.12
All of these characteristics of polyclonal Treg hamper their
clinical applications.
In contrast, adoptive transfer of antigen-specific Treg has
been shown to prevent and treat T cell–mediated inflammatory
diseases with high efficiency. In animal models, small numbers
of antigen-specific Treg can suppress experimental autoimmune
diseases13 and prevent GVHD and allograft rejection in bone
marrow and solid organ transplantation.14,15 Importantly, the
transfer of antigen-specific Treg prevented target antigen-
mediated T-cell responses, such as GVHD and allograft rejec-
tion, but did not compromise host general immunity, including
the graft-versus-tumor activity and antiviral immunity.5,15-17
Based on these studies, antigen-specific Treg has substantial
promise for human immunotherapy.
The reliable induction and expansion of rare antigen-specific
Treg are technically challenging. Currently, several protocols for
murine antigen-specific Treg induction and expansion have been
reported in which either purified CD4CD25 or CD4CD25
cells were cocultured with autologous dendritic cells (DCs) pulsed
with alloantigen in the presence of high-dose IL-2 or directly
cocultured with allogeneic DCs.14,18–20 Similar protocol has also
been reported for generation of human antigen-specific Treg
recently.21 In this protocol, antigen-specific CD4CD25 Treg can
be generated using the coculture of CD4CD25 T cells with
allogeneic monocyte-derived DCs. However, the large-scale in
vitro expansion of alloantigen-specific Treg is difficult because of
certain features of DCs. For example, DCs are relatively rare in
peripheral blood and are usually derived from apheresis or marrow
sources, including monocytes.22,23 Further, DCs are not homoge-
neous and include multiple subsets with different functional
capacities.24 Finally, there is no effective way to expand human
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DCs so far.25 In addition, the current approaches to generate human
DCs in vitro are expensive and laborious.26
Schultze et al reported a simple and low-cost method to expand
large number human CD40-activated B cells up to 105- to 106-fold
from human peripheral blood mononuclear cells (PBMCs).27 These
expanded B cells are effective as APCs and can efficiently induce
antigen-specific T cells and cytotoxic T lymphocytes.26,27 In this
study, we developed a novel protocol to induce and expand highly
efficient human alloantigen-specific Treg in large-scale by cocul-
ture of naive CD4CD25 T cells with human allogeneic CD40-
activated B cells without any exogenous cytokines. The induced
alloantigen-specific Treg were CD45RO and CCR7 memory
cells, and expressed the common Treg markers (CD25 and Foxp3),
as well as the lymph node homing receptor CD62L (L-selectin).
Importantly, they were also identifiable by a CD4high surface
phenotype. The suppressive function of these CD4highCD25Foxp3
alloantigen-specific Treg was cell-cell contact dependent but did
not involve cell-mediated cytotoxicity. This novel approach for in
vitro induction and expansion of alloantigen-specific Treg should
facilitate the development of Treg-based clinical immunotherapy.
Methods
Generation of CD40-activated B cells
Human peripheral blood was obtained from healthy donors in accordance
with the Declaration of Helsinki and with ethical committee approval from
the Institutional Review Boards of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster. PBMCs were isolated by density
gradient centrifugation as previously reported.28,29 B cells from PBMCs
were stimulated via CD40 using NIH3T3 cells transfected with the human
CD40 ligand (t-CD40-L cells) as described previously.27 The transfected
cells have been stable for human CD40L expression over a period of
5 years, and no other human molecules are expressed on t-CD40-L cells.27
The lethally irradiated (96 Gy) t-CD40-L cells were plated on 6-well plates
(Corning Life Sciences, Acton, MA) at a concentration of 0.4  105
cells/well in medium containing 45% Dulbecco modified Eagle medium
(Invitrogen, Carlsbad, CA), 45% F12 (Invitrogen) 10% fetal calf serum,
2 mM glutamine (Invitrogen), and 15 g/mL gentamicin (Invitrogen). After
an overnight culture at 37°C in 5% CO2, t-CD40-L cells were adherent and
ready for B-cell culture. PBMCs at 2  106 cells/mL were cocultured at
37°C in 5% CO2 with t-CD40-L cells in the presence of IL-4 (2 ng/mL;
R&D Systems, Minneapolis, MN) and cyclosporin A (5.5  107 M) in
Iscove modified Dulbecco medium (Invitrogen) supplemented with 10%
human AB serum, 50 g/mL transferrin (Roche Diagnostics, Indianapolis,
IN), 5 g/mL insulin (Sigma-Aldrich, St Louis, MO), and 15 g/mL
gentamicin (Invitrogen). The concentration of cyclosporin A used here was
found to only suppress T-cell proliferation without affecting B-cell growth.
Cultured cells were transferred to the wells of new plates with fresh
irradiated t-CD40-L cells every 3 to 5 days. Once the cultured PBMCs were
75% CD19, they were cultured at concentrations of 0.75 to 1.0  106 cells/
mL. The number of viable cells and CD19 B cells was analyzed by flow
cytometry every 3 to 5 days. After 14 days of coculture, more than 95% of
the viable suspended cells are CD19 positive. B cells were cryopreserved
for future use. For coculture with CD4 T cells, the cryopreserved
CD40-activated B cells were always centrifuged on a Ficoll-Hypaque
density gradients and washed twice in phosphate-buffered saline to remove
nonviable cells, including remaining t-CD40-L cells. Alternatively, t-CD40-L
cells were replaced by different concentrations of the soluble hexameric
CD40-L (sCD40-L; Alexis Biochemicals, Lausen, Switzerland) to expand
B cells.30
T-cell isolation
Human CD4 or naive CD4 T cells were isolated from healthy donor
PBMCs by negative selection using a CD4 T-cell isolation kit or a naive
CD4 T-cell isolation kit (Miltenyi Biotec, CA) for depletion of cells
expressing CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR/, and
CD235a (glycophorin A) (for CD4 T cells) or depletion of CD8, CD14,
CD16, CD19, CD36, CD56, CD123, TCR/, CD235a, and CD45RO
(for naive CD4 T cells). The CD25 cells were further depleted by
positive selection with directly conjugated anti-CD25 magnetic microbeads
(Miltenyi Biotec, Auburn, CA) after the double-column depletion proce-
dures. After the double-column depletion procedure, the CD4CD25
or CD4CD45RACD45ROCD25 cells were routinely more than
99% pure by flow cytometric analysis. In some cases, the CD25 cells
were sorted by FACSAria, and the purity of CD4CD25 or
CD4CD45RACD45ROCD25 cells was greater than 99.9%.
Allogeneic stimulation assay to induce and expand Treg
Freshly purified CD4CD25 or CD4CD45RACD45ROCD25
T cells were cocultured with allogeneic CD40-activated B cells at a 10:1
T cell–to–B cell ratio in the RPMI 1640 medium with 10% heat-inactivated
human AB serum. For some experiments, the T cells were labeled with
carboxyfluorescein succinimidyl ester (CFSE) as previously reported
before coculture with CD40-activated B cells.18 In the repeated stimu-
lation experiments, the allogeneic CD40-activated B cells were added
every 7 days of culture. In some experiments, human recombinant IL-2
(1000 IU/mL) was added in the culture medium. Functional and phenotypi-
cal hallmarks of the induced and expanded T cells were examined at the
indicated time of culture. The expansion of the cells was determined by
counting trypan blue–excluding cells.
Flow cytometric analysis
Cells were phenotypically analyzed using a FACSAria. The following
fluorescence-conjugated monoclonal antibodies (mAbs) were used. Anti–
CD4-PE-Cy5, anti–CD45RA-PE, and anti-CD45ROAPC were purchased
from Invitrogen. Anti–CD25APC, anti–CD62L-APC, anti–CD27-PE,
anti–CD44-PE, anti–CCR7-PE, anti–cytotoxic T lymphocyte antigen-4
(CTLA-4)–PE, anti–GITR-PE, and their isotype-matched control Abs of
irrelevant specificity were purchased from BD Biosciences (San Jose, CA).
Intracellular staining was performed after cell fixation and permeabiliza-
tion, using Fix and Perm reagents (BD Biosciences) as we reported
before.28,29,31 The following mAbs were used: anti–CTLA-4-PE (BD
Biosciences), anti–GITR-PE (BD Biosciences), anti–IL-10-PE (R&D Sys-
tems), anti–transforming growth factor- (TGF--PE; IQ Products, Gro-
ningen, The Netherlands), and anti–IL-2 (BD Biosciences). For Foxp3
staining, the human Foxp3 staining kit (eBioscience, San Diego, CA) was
used as we described before.32
Mixed lymphocyte reaction assays
The suppressor capacity of T cells induced and expanded in coculture with
allogeneic CD40-activated B cells was studied in a mixed lymphocyte
reaction (MLR) coculture suppression assay, as we described before with
some modifications.23,32 CD4CD25 or CD4CD45RACD25 T cells
were cocultured with allogeneic CD40-activated B cells (target) for 7 or
21 days, after which time CD4mediumCD25 and CD4highCD25 T cells
were sorted by FACSAria. The purity of sorted cells was routinely more
than 99%. The sorted CD4highCD25 and CD4mediumCD25 cells referred to
as “suppressor” were titrated and added at the start of MLR assays,
consisting of a total of 5  104 responder CD4CD25 T cells from same
donor of CD4medium/CD4high cells and 5  104 gamma-irradiated (30 Gy)
target PBMCs from same donor of allogeneic B cells. Antigen specificity
was examined in the cocultures that were performed with third-party
stimulator PBMCs that were fully class I and II HLA-mismatched with the
(target) allogeneic B cells. Proliferation was analyzed by [3H]-thymidine
incorporation assay as described previously,33,34 with incorporation ex-
pressed as the mean plus or minus SEM cpm of 4 to 6 wells/condition.
Cytotoxic capacity of the induced and expanded cells was determined
by the Live/Dead cell-mediated cytotoxicity kit (Invitrogen).35 Similar
MLR coculture was set except that responder CD4CD25 T cells were
labeled with 3, 3-dioctadecyloxacarbocyanine. After 2 and 3 days of MLR
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culture, cells were stained with propidium iodide at 37°C for 2 hours and
then analyzed by flow cytometry. Back gating on the green fluorescent
target cells, the propidium iodide-positive cells were evaluated for the
percentage of lysed cells.
The contact dependency of CD4highCD25 Treg was examined in
Transwell experiments using 24-well plates. Briefly, 2  105 responder
CD4CD25 cells and 2  105 gamma-irradiated stimulator PBMCs
(target) were cocultured in the lower compartment of the well. A total
of 2  105 of CD4highCD25 Treg were cultured in the Transwell insert
(0.4 m pore size; Millicell; Millipore, Billerica, MA). On day 3 of the
cocultures, equivalent culture volumes were transferred from the lower
compartment of the 24-well plate to a 96-well, round-bottom plate and
analyzed for proliferation.
Blocking studies were performed in the presence of the neutralization
mAbs directly against CTLA-4 (10 g/mL; Ancell, Bayport, MN), IL-4
(10g/mL, R&D Systems), IL-10 (10g/mL; eBiosciences), glucocorticoid-
induced TNF receptor (GITR; 2 g/mL, R&D Systems), TGF- (2 g/mL,
R&D Systems), and their relevant isotype controls.
Statistical analysis
Graphs and statistical analyses were performed with the use of Prism 4.00
for Windows software (GraphPad Software, San Diego, CA). P values of
.05 or less were considered significant.
Results
CD40-activated B cells expanded by incubation with
either CD40-ligand transfected cells or soluble
hexameric CD40-ligand express high levels of MHC
and costimulatory molecules
As in a previous report,27 nontransformed CD40-activated B cells
could be expanded from circulating B cells contained in PBMCs
by treatment with CD40-ligand (CD40-L) transfected NIH3T3
(t-CD40-L) cells, IL-4, and low concentrations of cyclosporin A.
The purity of CD19CD3 B cells was at least 83% by day 8 and
more than 95% at day 12. By 28 to 32 days of culture, more than
99% of cells were the CD19CD3 B cells (data not shown). To
evaluate the expansion rate of B cells, we monitored the absolute
number of CD19CD3 cells generated from 5.0 mL of peripheral
blood from 8 unselected healthy adult donors. We found that, after
32 days of culture, 8.1 to 54.3  107 CD40-activated B cells could
be generated (Figure 1A). We next determined whether soluble
hexameric CD40-ligand (sCD40-L) could replace t-CD40-L for
B-cell activation and expansion, as t-CD40-L are xenogenic and
would be potentially undesirable contaminants in adoptive immu-
nity protocols in humans. We found that sCD40-L expanded B cells
in a dose-dependent fashion (Figure 1B). At the concentration of
1.0 g/mL, it was similarly effective as t-CD40-L in promoting
B-cell expansion (Figure 1B). CD40-activated B cells generated
using either sCD40-L or tCD40-L expressed high levels of major
histocompatibility complex (MHC) class I and II molecules and
costimulatory molecules CD80 and CD86 at 8 days (Figure 1C),
and the expression of these molecules remained stable thereafter
(data not shown).
Human alloreactive CD4high cells induced by CD40-activated
B cells are Treg
To determine whether allogeneic CD40-activated B cells can
induce Treg from CD4CD25 T cells, purified circulating
CD4CD25 T cells (purity 	 99%) were stimulated with alloge-
neic CD40-activated B cells for 7 days. Surprisingly, a new cell
subset with significantly up-regulated levels of CD4 surface
expression was induced after 5 days of allostimulation, and most of
these CD4high cells lost CD45RA expression (Figure 2A) and
acquired CD45RO expression (data not shown). Furthermore, most
of these CD4high cells also lost CFSE staining, whereas the
CD4medium cells still maintained their CFSE content (Figure 2A),
suggesting that the induced CD4high cells were proliferating alloreac-
tive cells. These presumed alloreactive CD4high cells expressed
CD25 and Foxp3, whereas CD4medium cells did not express these
2 Treg markers (Figure 2B). Together, these findings indicated
that CD40-activated B cells preferentially expanded a
CD4highCD25Foxp3 Treg cell population. Similar results were
also found using highly purified CD4CD25 T cells (pu-
rity 	 99.9%) sorted by fluorescence-activated cell sorting (FACS)
in this coculture system (data not shown). Thus, it is unlikely that
the CD4highCD25Foxp3 Treg obtained were the result of an
expansion of CD4CD25 T cells contaminating the initial culture.
To examine the function and alloantigen specificity of the
induced CD4highCD25Foxp3 Treg from CD4CD25 cells, the
MLR assay was used. As shown in Figure 2C, after 7 days of
allostimulation, CD4highCD25 and CD4mediumCD25 cells were
sorted by FACS and then added in the MLR assay. CD4medium cells
did not suppress either the original target or third-party alloantigen-
induced proliferation, whereas CD4highCD25 cells suppressed
both target- and third-party antigen–induced proliferations, al-
though their suppressive effect on third-party alloantigen–induced
proliferation was lower than that mediated by the target alloantigen
(Figure 2C). Thus, CD4highCD25 Treg generated from
CD4CD25 cells effectively suppressed in the MLR assay, but
their suppression was not alloantigen-specific.
CD40-activated B cells can induce alloantigen-specific
CD4highCD25 Treg from naive CD4CD25 cells
We next determined whether alloantigen-specific Treg could
be generated from purified naive CD4CD25 cells
Figure 1. CD40 activation is highly effective in generating large numbers of
CD40-activated B cells that express high levels of MHC and costimulatory
molecules. (A) Overall expansion of CD40-activated B cells from 8 different persons.
CD40-activated B cells were generated by the coculture of PBMCs from 5 mL of
peripheral blood with CD40L-transfected NIH3T3 (t-CD40-L) cells. (B) sCD40-L is as
efficient as t-CD40-L cells at expanding human B cells in culture. CD40-activated
B cells were generated by t-CD40-L cells or different concentrations of soluble
hexameric CD40-L. The results shown are representative of 3 independent experi-
ments. (C) Expression of CD80, CD86, and MHC class I and II on the CD40-activated
B cells cultured for 8 days (solid histograms). The filled histograms were obtained
with relevant isotype controls. Data shown here are representative of B-cell
populations obtained from 8 different healthy adult donors.
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(CD4CD45RACD45ROCD25) by coculture with alloge-
neic CD40-activated B cells. As in the case of unfractionated
CD4CD25 T cells, naive CD4CD25 cells expanded by
coculture with CD40-activated B cells also acquired a CD4high,
CD25, and Foxp3 phenotype after 7 days of culture (Figure
3A). Furthermore, these CD4highCD25Foxp3 Treg underwent
7 or 8 cell divisions by 7 days of allostimulation (Figure 3A). In
contrast, CD4medium cells neither divided nor expressed CD25
and Foxp3 (Figure 3A).
We further examined the suppressive capacity and alloantigen
specificity of the CD4highCD25 Treg induced from naive pre-
cursors. These CD4highCD25 Treg significantly suppressed the
original target alloantigen-induced proliferation, whereas
CD4mediumCD25 cells did not show substantial suppressive ability
(Figure 3B). Importantly, the induced CD4highCD25 Treg were
unable to suppress a third-party alloantigen-induced proliferation
(Figure 3B). These data demonstrate that CD4highCD25 Treg
induced from naive CD4CD25 T cells by allogeneic CD40-
activated B cells are alloantigen-specific.
The CD4highCD25 Treg generated from naive precursors had
very high suppressive potential: Even at a cell ratio of 1:256 for
Treg/responder cells (CD4CD25), there was approximately 50%
suppression of target alloantigen-stimulated proliferation. At a
Treg/responder cell ratio of 1:16 or higher, the target alloantigen-
stimulated proliferation was almost completely inhibited (Figure
3B). This highly suppressive potential was also evident with
unsorted CD4 T cells containing approximately 80% of
CD4highCD25 T cells and 20% of CD4mediumCD25 T cells,
indicating that contaminating CD4mediumCD25 cells do not inter-
fere with Treg activity and therefore do not need to be removed by
FACS sorting (Figure 3B).
Figure 2. Human alloreactive CD4high cells induced by CD40-activated B cells
are Treg. (A) CD4 expression in CD4CD25 T cells stimulated with allogeneic
B cells for 5 days (top panels), and its relationship with cell proliferation based on the
loss of CFSE label and CD45RA expression. Top panels represented the T cells
gated on CD4. The percentage of CD4 T cells in each gate is indicated. For the
bottom panel, open histograms indicate the CFSE fluorescence intensities of the
unstimulated control T cells, and the filled histograms represent the CFSE fluores-
cence intensities of the allostimulated T cells. The numbers in each histogram
represent the percentage of cells that have undergone mitosis from each cell subset.
(B) CD4high cells express both CD25 and Foxp3. The dot plot on the left shows CD25
expression after 5 days of allostimulation. Open histograms on the right show the
Foxp3 expression, and filled histograms indicate the isotype controls. The results
shown are representative of 4 different experiments. (C) CD4highCD25 Treg
generated from CD4CD25 T cells potently suppressed MLR in an antigen-
nonspecific manner. Freshly purified CD4CD25 T cells were cocultured with
CD40-activated allogeneic B cells for 7 days. The sorted CD4highCD25 (f) and
CD4mediumCD25 () cells were added into MLR culture system as described in
“Mixed lymphocyte reaction assays.” Proliferation (y-axis) is shown for 3 days of
MLR. The results shown are representative of 5 different experiments.
Figure 3. Human CD4high Treg induced from naive CD4CD25 T cells by
CD40-activated allogeneic B cells are alloantigen-specific Treg. (A) Characteris-
tics of CD4high Treg induced from naive CD4CD25 T cells. Freshly purified naive
CD4CD25 T cells were labeled with CFSE and cocultured with CD40-activated
allogeneic B cells for 7 days. Representative data of CD4 and CD25 expression (left
panel), CFSE dilution (top right panel), and Foxp3 expression (bottom right panel)
from 6 independent experiments. Open histograms show the CFSE fluorescence
intensity (top right panel) and Foxp3 expression (bottom right panel) of
CD4mediumCD25 cells. Filled histograms represent the CFSE fluorescence intensity
(top right panel) and Foxp3 expression (bottom right panel) of CD4highCD25 cells.
(B) CD4highCD25 Treg generated from naive CD4CD25 T cells potently sup-
pressed MLR in an alloantigen-specific manner, and unsorted CD4 T cells
generated from naive CD4CD25 T cells had similar suppressor capacities in MLR.
Freshly purified CD4CD45RACD25 T cells were cocultured with CD40-activated
allogeneic B cells for 7 days. The sorted CD4highCD25 (f) and CD4mediumCD25
(), and unsorted CD4 T cells () were added into MLR culture system as
described in “Mixed lymphocyte reaction assays.” Proliferation (y-axis) was shown for
day 3 of MLR. The results shown are representative of 8 independent experiments.
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Characteristics of CD4highCD25Foxp3
alloantigen-specific Treg
We further characterized the phenotype of the induced
CD4highCD25Foxp3 alloantigen-specific Treg population. CD25
was significantly up-regulated from low basal levels by day 3 of
culture, and more than 90% and 95% of CD4high cells expressed
CD25 at day 3 and day 10, respectively, whereas there was no
CD25 up-regulation on CD4medium cells for up to 10 days of culture
(Figure 4A). The memory T-cell marker CD45RO was also
up-regulated in both CD4high and CD4medium cells, but 95% of
CD4high cells were CD45RO after 10 days of culture and only
approximately 50% of CD4medium cells had this surface phenotype.
Unlike previous reports indicating that the expression of CD27 and
CD44 can discriminate functional CD4CD25 Treg in human and
mice,36,37 we found no significant differences in CD27 and CD44
surface expression by CD4high Treg compared with CD4medium
T cells or within the population of CD4highCD25 Treg (Figure
4A). Most of the induced CD4high Treg lost their CCR7 expression
after 6 days of culture, suggesting they had a memory/effector-like
phenotype and tendency to migrate to inflamed tissues rather than
undergo recirculation between the lymph nodes and blood.38
However, CD4high Treg still maintained high levels of CD62L
expression, which probably would confer effective lymph node
homing via high endothelial venules.
We next examined the expression of proteins previously
implicated in the suppressive activity of Treg, including CTLA-4
(or CD152), GITR, IL-10, and TGF-.39 Figure 4 shows that cell
surface CTLA-4 and GITR were clearly detectable by day 3 and
gradually increased such that approximately 30% and 45% of
CD4high Treg expressed surface CTLA-4 and GITR, respectively,
between day 6 and day 7. This was followed by a gradual decline in
surface expression. Total CTLA-4 and GITR expression displayed
different kinetics in that they gradually increased from day 3 so that
approximately 60% and 30% of CD4highCD25 Treg expressed
CTLA-4 and GITR, respectively, after 10 days of culture based on
intracellular staining (Figure 4B). In contrast, CD4mediumCD25
T cells expressed little or no CTLA-4 and GITR molecules on the
surface or intracellularly (Figure 4). Both CD4mediumCD25 cells
and CD4highCD25 Treg expressed little or no detectable IL-10 and
TGF- during 10 days of culture (Figure 4B). Taken together, these
data suggest that CTLA-4 or GITR, but not IL-10 and TGF-, are
potential mediators of CD4highCD25 Treg suppressive activity.
CD4highCD25 Treg lack cytotoxic capacity and suppress by a
mechanism that requires cell-cell contact and involves, in part,
CTLA-4 expression
To determine the mechanism of CD4highCD25 Treg suppression,
we first determined whether CD4highCD25 alloantigen-specific
Treg had cytotoxic activity to responder cells (CD4CD25), as
previous studies demonstrated that the suppression of Treg was
dependent on their cytotoxicity.40,41 CD4highCD25 Treg did not
kill responder cells or induce their apoptosis during 2 to 3 days of
MLR (Figure 5A), suggesting that the suppression of CD4highCD25
alloantigen-specific Treg was not mediated by cell-mediated
cytotoxicity.
We next determined whether CD4highCD25 suppression could
be mediated solely by soluble molecules released from Treg.
As shown in Figure 5B, the suppression was lost when the
responder cells were physically separated from the induced
CD4highCD25 Treg in a transwell culture system. The addition of
neutralizing mAb for IL-10, TGF-, IL-4, or GITR into MLR
cultures had little or no effect on the ability of CD4highCD25
Treg to suppress alloantigen-specific proliferation (Figure 5C).
In contrast, antibody blockade of CTLA-4 partially reversed
CD4highCD25 Treg suppression (Figure 5C). Together, these data
suggest that the CD4highCD25 Treg-mediated suppression of
alloantigen responses is cell-cell contact dependent and mediated,
in part, by CTLA-4.
CD4highCD25 Treg can be continuously expanded by
CD40-activated B cells in large-scale without loss of function
and exogenous IL-2 does not enhance cell expansion
We examined the ability of 3 weeks of coculture of naive
CD4CD25 T cells with allogeneic CD40-activated B cells to
Figure 4. Characteristics of CD4highCD25 alloantigen-
specific Treg. Freshly purified naive CD4CD25 T cells
were cocultured with CD40-activated allogeneic B cells
for the indicated time. The expression of cell surface
markers (A) and intracellular cytokines (B) was deter-
mined and analyzed by FACS as described in “Flow
cytometric analysis.” The percentage of positive cells for
each cell surface marker or intracellular cytokine within
the CD4highCD25 and CD4mediumCD25 subsets are
indicated. The results shown are representative of 4 inde-
pendent experiments.
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generate Treg, in which freshly generated CD40-activated B cells
were added weekly. As shown in Figure 6A, CD4highCD25 Treg
gradually increased, and more than 92% of T cells in culture were
the CD4highCD25 Treg at day 21 (Figure 6A). Using 10 healthy
randomly selected adult blood donors, we were able to expand
CD4highCD25 Treg 6.4  105- to 1.6  107-fold during 21 days of
culture (Figure 6B). This expansion did not require exogenous
IL-2, as its addition did not increase the generation of CD4highCD25
Treg cells (Figure 6C). To more precisely determine the rate of
expansion, we used a standard number of naive CD4CD25
T cells (106) at the beginning of the culture and found that
approximately 8.3  106 (range, 5.4-11.3  106) of CD4highCD25
Treg could be generated from every 106 of naive CD4CD25
T cells in 10 unselected donors (Figure 6D). Furthermore, ex-
panded CD4highCD25 Treg evaluated at 21 days of culture had
similar suppressive ability and alloantigen specificity (Figure 6E)
as Treg generated over a shorter period of in vitro culture. In
addition, these Treg still maintained their high levels of Foxp3
expression (data not shown). Together, these results demon-
strate that CD40-activated B cells can induce and expand
CD4highCD25Foxp3 alloantigen-specific Treg at a scale that is
probably to be relevant for clinical immunotherapy.
Discussion
In this study, we describe a reliable method to generate human
alloantigen-specific Treg in vitro from naive CD4 T-cell precur-
sors. This, to best of our knowledge, is the first report about the
large-scale generation of human antigen-specific Treg. Using
allogeneic CD40-activated B cells, we induced naive CD4 T-cell
precursors to differentiate and expand into alloantigen-specific
CD4highCD25Foxp3 Treg with robust regulatory activity that
was alloantigen-specific. By repeatedly stimulating naive CD4
T cells with allogeneic CD40-activated B cells for 21 days, we
could routinely generate 6 to 11  106 alloantigen-specific Treg
from every 106 naive CD4CD25 T cells; these numbers of naive
CD4 T cells can typically be isolated from 5 to 8 mL of peripheral
blood. Thus, this is a practical approach for the generation of
relatively large numbers of human antigen-specific Treg, which
should facilitate the development of clinical immunotherapy based
on the adoptive transfer of Treg.
Our protocol is different from those previously reported for
allogeneic Treg induction and expansion in that we used CD40-
activated B cells as APCs rather than allogeneic monocyte-derived
DCs or PBMCs.21,42 CD40-activated B cells have an important
advantage for this purpose in that they can be readily expanded in
vitro to a relatively large numbers (Figure 1), whereas, in contrast,
monocytes differentiating in vitro into DCs do not undergo cell
division.22 Cryopreserved CD40-activated B cells also retain their
APC function on thawing and are relatively cost-effective to
produce.26,27 In addition, because B cells stimulated with t-CD40-L
cells or recombinant sCD40-L were equally effective at generating
alloantigen-specific Treg, the use of sCD40-L may significantly
improve the clinical applicability of the procedure.
We confirmed the work of Schultze et al26,27,43: that activation of
B cells by CD40 engagement using CD40-ligand transfected
murine fibroblasts resulted in high levels of expression of MHC
class I and class II and the CD80 and CD86 costimulatory
molecules. Similar levels of expression of these molecules could be
achieved using hexameric human CD40-ligand, indicating that
engagement of CD40 was the essential signal and that other ligands
Figure 5. CD4highCD25 alloantigen-specific Treg have no cytotoxic capacity, and their suppressor function is dependent on cell-cell contact and partially relies on
CTLA-4 expression. CD4highCD25 Treg or CD4mediumCD25 T cells were sorted after 7 days of allostimulation as shown in Figure 3B. (A) Cytotoxic capacity of induced
CD4highCD25 Treg. (B) The alloantigen-specific suppressor function of CD4highCD25 Treg is cell-cell contact dependent. (C) Neutralizing anti–CTLA-4 mAb partially reverses
the alloantigen-specific suppression mediated by CD4highCD25 Treg, but neutralizing mAbs to IL-4, IL-10, TGF-, and GITR fails to reverse that suppression. Responder (R)
CD4CD25 and gamma-irradiated stimulator PBMC (S) were cocultured with or without sorted CD4highCD25 Treg or CD4mediumCD25 T cells. The cytotoxic activities (A) of
human IL-2–activated NK cells against K562 cells were set as positive controls (PC). Stimulator (S) or responder (R) cells alone were set as controls. For transwell
experiments (B), the same amount of responder (R) and stimulator (S) cells were plated in the bottom wells of a transwell system. The top well insert was inoculated with same
amount of sorted CD4highCD25 Treg. For the blocking experiments (C), the neutralization mAbs () and their relevant isotype controls (f) were added in the coculture
system. Proliferation (y-axis) is shown for day 3 of cultures. Data for 4 different experiments are shown (n 
 4). The 2-tailed unpaired Student t tests were used for
comparison. *P  .01.
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potentially provided by murine fibroblasts were dispensable for
B-cell activation. In contrast to prior work26,27,43 in which autolo-
gous CD40-activated B cells were used as APCs in conjunction
with IL-2 and IL-7 to generate effector T-cell responses, we found
that allogeneic Treg generation did not require the addition of
exogenous cytokines. We speculate that the absence of exogenous
cytokines, such as IL-7, and using allogeneic rather than autolo-
gous CD40-activated B cells in our system may account for why
we observed the differentiation and marked expansion of alloge-
neic Treg rather than effector T cells in our CD40-activated
B-cell/naive CD4 T-cell coculture system. Our findings are also
consistent with growing evidence that some subsets of B cells exert
regulatory activity and that this may involve in certain contexts an
enhancement of Treg activity.44
Using coculture of allogeneic CD40-activated B cells with total
or naive CD4CD25 T cells, we generated CD4highCD25Foxp3
Treg after 5 to 7 days of culture (Figures 2, 3). Importantly, we
demonstrated that CD4highCD25Foxp3 Treg generated from
naive CD4CD25 T-cell precursors were alloantigen-specific
(Figure 3), whereas those derived from total CD4CD25 T cells,
which included both naive and memory cells, had no antigen
specificity (Figure 2). Treg generated from memory CD4CD25
T cells were also found to have no antigen specificity and could
suppress both target and third-party antigen stimulated MLR (data
not shown). Consistent with our findings, other groups have also
shown that Treg could be generated from both naive and memory
CD4 T cells after coculture with allogeneic DCs and that these
2 sources of Treg were similarly effective in suppression.21,45
However, differences in the antigen specificity of these Treg were
not investigated in these studies.21,45 The reasons underlying the
marked difference in antigen specificity between the Treg gener-
ated from total CD4CD25 and naive CD4CD25 T cells are
still unclear, but it is plausible that Treg generated from antigen-
experienced memory cells present in total CD4CD25 T cells
may account for this difference.
IL-2 is critical for maintaining Treg survival, although it is
dispensable for the induction of CD4CD25Foxp3 Treg.32,46 It
was reported that the in vitro generation of polyclonal or alloantigen-
specific human Treg required high-dose exogenous IL-2.11,36
However, in our culture system, it was unnecessary to add
exogenous IL-2 for inducing and expanding alloantigen-specific
CD4highCD25Foxp3 Treg (Figure 6D), most probably because
the allogeneic CD40-activated B cells can secrete substantial
amounts of IL-2 (Figure S1, available on the Blood website; see the
Supplemental Materials link at the top of the online article). This
lack of a requirement for exogenous cytokines could significantly
reduce the cost for generation of alloantigen-specific Treg.
Importantly, we also observed a significant up-regulation of the
CD4 molecule on T cells after the allostimulation of naive or total
CD4CD25 T cells with allogeneic CD40-activated B cells.
Based on the expression of CD4 and CD25, the allostimu-
lated human CD4 T cells could be separated into 2 sub-
sets: CD4highCD25 and CD4mediumCD25 cells (Figures 2,3).
We further demonstrated that the CD4highCD25 but not
CD4mediumCD25 cells were Treg that expressed Foxp3 and had
highly suppressive capacities (Figures 2,3), raising the possibility
that the CD4high might be a marker for human Treg in other
contexts, a possibility that we are currently investigating.
The alloantigen-specific CD4highCD25Foxp3 Treg generated
in our system were CD45RO and CCR7 memory cells and
expressed a high level of lymph node homing receptor CD62L
(Figure 3). This suggests that these cells might potentially be useful
for migrating to peripheral lymphoid tissues draining graft sites to
suppress T cell–mediated allograft rejection and GVHD. It has
previously been demonstrated that ex vivo–expanded Treg can
retain their regulatory activity and migrate appropriately into the
peripheral lymphoid organs in the recipient if they express a high
level of CD62L.12,47
We also demonstrated that induced alloantigen-specific
CD4highCD25Foxp3 Treg expressed CTLA-4 and GITR but had
minimal secretion of TGF- or IL-10 (Figure 4). Other surface
markers, such as CD27 and CD44, were previously reported by
others to discriminate between functional Treg and non-Treg.36,37
However, we did not find any significant difference in the
expression of CD27 and CD44 between the CD4highCD25Foxp3
Treg and CD4mediumCD25Foxp3 non-Treg produced with the
B-cell coculture system.
In functional analysis, we demonstrated that the alloantigen-
specific CD4highCD25Foxp3 Treg generated in our system could
completely block the alloantigen-stimulated MLR (Figure 3). With
these Treg, the marked suppressive effects could occur with as little
Figure 6. CD4highCD25 alloantigen-specific Treg can be continuously ex-
panded by CD40-activated B cells in large-scale without loss of function, and
exogenous IL-2 does not enhance this cell expansion. Freshly purified naive
CD4CD25 T cells were cocultured with CD40-activated allogeneic B cells for the
indicated time. (A) The percentages of CD4highCD25 and CD4mediumCD25 cells in
the cultures (n 
 10). (B) Expansion of CD4highCD25 alloantigen-specific Treg from
10 different persons. The expansion was normalized for the CD4highCD25 cells, and
the fold increase of the CD4highCD25 was shown. (C) Naive CD4CD25 were
cocultured with CD40-activated allogeneic B cells with or without IL-2. The expansion
was normalized for the CD4highCD25 cells, and the fold increase of the CD4highCD25
is shown (n 
 4). (D) Absolute numbers of CD4highCD25 alloantigen-specific Treg
generated from 106 naive CD4CD25T cells (n 
 10). (E) CD4highCD25 alloantigen-
specific Treg induced and expanded by CD40-activated B cells for 21 days remain
functional. Freshly purified naive CD4CD25 T cells (responder) were cocultured
with CD40-activated allogeneic B cells (target antigen) to induce and expand
CD4highCD25 Treg for 21 days with replacement of B cells every 7 days. The sorted
CD4highCD25 and CD4mediumCD25 cells were added into the MLR culture system
as described in “Mixed lymphocyte reaction assays.” Data shown here are represen-
tative of 3 independent experiments.
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as about 718 suppressors (1:64 ratio) in a culture of 50 000
responding CD4CD25 T cells and 50 000 allogeneic PBMC
stimulators. These effects are more potent than those previously
reported for freshly isolated or expanded human polyclonal and
alloantigen-specific Treg9-11,21 and again suggest the potential
clinical utility of the Treg generated by CD40-activated B cells in
adoptive immunotherapy.
The mechanisms of Treg suppressive function still remain
largely unknown. Evidence from in vitro and in vivo studies in both
human and rodents indicate that direct cell-cell contact is required
and that some immunoregulatory cytokines may also be involved
in the suppression of effector T-cell activity.39 We also demon-
strated that the suppressive functions of CD4highCD25Foxp3
Treg were cell-cell contact dependent and partially relied on
CTLA-4 expression, consistent with previous observations in
natural and in vitro expanded human Treg.36,48,49 Consistent with
the previous finding that IL-10, TGF-, and GITR are dispensable
for the suppressive function of CD4CD25 Treg,9,11,21 we also
demonstrated that these 3 molecules were not required for suppres-
sion by CD4highCD25Foxp3 Treg (Figure 5). Some previous
studies have also suggested that the suppression of Treg may be
mediated by their cytotoxicity,40,41 but we did not find that our
induced CD4highCD25Foxp3 Treg had cytotoxic activities (Fig-
ure 5). In addition, the possibility of involvement of Th2 response
in MLR was also excluded because blockade of IL-4 failed to
inhibit the suppression of CD4highCD25Foxp3 Treg (Figure 5).
In conclusion, we have developed a relatively simple and
low-cost protocol using allogeneic CD40-activated B cells to
induce and expand highly efficient human alloantigen-specific
CD4highCD25Foxp3 Treg from naive CD4CD25 T cells
in large scale. This may facilitate the clinical applications of
Treg-based immunotherapy using in vitro induced and expanded
alloantigen-specific Treg to induce donor-specific transplantation
tolerance, although it remains to be shown whether this applies to
the in vivo situation.50 Similar strategies, that is, induction and
expansion of autoantigen-specific Treg using antigen-pulsed autolo-
gous CD40-activated B cells, could be exploited in the treatment of
autoimmune diseases in which the target self-antigens are known.
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